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A total of 600 patients from cancer centres throughout the UK identified their most preferred and most disliked descriptions of
randomisation found in current patient information sheets and websites. The CancerBACUP description, which describes both the
process of randomisation and why it is done, was most preferred 151 out of 533 (28%) patients. The NCI description was viewed as
overly technical and most disliked 185 out of 483 (38%) patients.
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There is an increasing expectation that patients should participate
actively in decision making and evidence that properly informed
patients are more likely to adhere to treatment (Epstein et al,
2004); thus, communicating clearly with patients and their
relatives is paramount. One discussion that challenges many
health professionals, even those with previous training in general
communication skills (Jenkins et al, in press), is talking about
randomised clinical trials (RCTs). The trial dialogue has many
aspects that must be explained clearly and be tailored to an
individual’s needs and level of understanding to enable educated
decision making. Random allocation of treatment is a key feature
that patients have to appreciate prior to giving informed consent
(Robinson et al, 2004).
The concept of randomisation produces difficulties for both
patients and health professionals (Featherstone and Donovan, 1998,
2002; Fleissig et al, 2001; Kerr et al, 2004; Robinson et al, 2004;
Simon et al, 2004) and among members of the public (Corbett et al,
1996; Kerr et al, 2004; Robinson et al, 2004). A series of studies
exploring lay conceptions of the scientific and ethical justifications
for random allocation and equipoise showed that while most
participants could correctly identify whether or not a method such
as tossing a coin was random, they did not find randomisation itself
acceptable nor that a clinician would not know which treatment
was best (Kerr et al, 2004; Robinson et al, 2004).
Although providing accurate ethical and understandable de-
scriptions of randomisation is important, there is surprisingly little
direct research elucidating the preferences of patients (Corbett
et al, 1996; Featherstone and Donovan, 2002; Jenkins et al, 2002;
Simon et al, 2004).
Patient information sheets about RCTs describe the randomisa-
tion process in a variety of ways, from ‘allocate patients to a
treatment group at random (this means by chance, a bit like
drawing lots)’ (TACT trial) (TACT – Standard anthracycline-based
chemotherapy with fluorouracil, epirubicin and cyclophosphamide
or epirubicin and CMF vs FEC followed by sequential docetaxel as
adjuvant treatment for women with early breast cancer) ‘rando-
misation means that neither you nor your doctor picks the
treatment, but a computer will decide’ (VICTOR trial) (VICTOR
– double blind, placebo-controlled trial of rofecoxib in colorectal
cancer patients following potentially curative therapy) to ‘rando-
misation means that for each patient a computer will be used in the
central office in London at the Medical Research Council Trials
Office to allocate by chance rather than a medical decision’ (REO4
trial) (RE04 – a trial of interferon-a, interleukin-2 and 5-
fluorouracil vs interferon-a alone in advanced renal cell cancer).
Explanations such as ‘drawing lots’ might sound somewhat
chancier than phrases such as ‘a computer will decide’, but
suggesting that a computer will decide may subtly mislead patients
into believing that a considered decision based on their individual
clinical details will be made.
In a previous survey, the preferences of 200 cancer patients and
341 members of a healthy lay population were compared with the
most commonly used descriptions of 200 oncologists. The study
used the seven simulated descriptions of randomisation taken
from the only other publication on the subject at the time (Corbett
et al, 1996). Results showed that one explanation did not suit all.
Analogies for allocation of treatment such as a ‘toss of a coin’ were
disliked by 31% of patients and almost a quarter of the public,
although this was a favoured description used by 26% clinicians in
the survey (Jenkins et al, 2002). The primary limitations of this
publication was that it utilised the contrived descriptions
employed by the original Corbett study (Corbett et al, 1996). In
an effort to further inform health professionals, we performed
another preference survey using seven actual descriptions of
randomisation.
MATERIALS AND METHODS
Descriptions
The authors reviewed over 100 definitions of randomisation taken
from current patient information sheets and information websites.
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sFrom these, seven were chosen which provided a broad range of
those in frequent use (see Table 1). Presentation order of the
descriptions was varied in a balanced manner to prevent any bias
due to the effects of order. Patients were not aware of the origin of
each description.
Questionnaire
Patients read the following short scenario:
‘Imagine that you have an appointment with a specialist to talk
about how to treat your condition. The specialist tells you there
is a research trial going on in the hospital comparing different
treatments that are suitable for your illness. However, the only
scientific way to compare one treatment with another is for the
choice between the treatments to be made randomly’.
Patients were then asked to rate whether they found each
description ‘unclear’, ‘fairly clear’ or ‘very clear’, to indicate their
most preferred and disliked statement and then provide a reason
for their choice if they wished.
Sample
The questionnaire probed basic demographic details such as age,
sex, cancer site and previous trial experience but was anonymous.
In total, 43 doctors and nurses from 24 oncology centres across the
UK who had attended a communication in clinical trials course
were invited to distribute questionnaires to unselected patients
with cancer aged over 18 years attending their outpatient clinics.
Each questionnaire was attached to an information sheet with a
stamped addressed envelope. A total of 1128 questionnaires were
provided to healthcare professionals; of these, 600 were returned
giving a 53% response rate. This figure might be an underestimate,
as it is not known if all the questionnaires were actually
administered. The patient demographics are shown in Table 2.
The study had full MREC and R&D approvals.
Statistics
Statistical Package for the Social Sciences (SPSS) version 11.5 was
used for all statistical analyses.
RESULTS
Clarity of descriptions
Most patients indicated that descriptions were fairly or very clear,
percentages are shown in Table 3. There were no significant
differences in clarity ratings by age, sex, previous trial experience
or sociodemographic characteristics.
Table 1 Descriptions of randomisation
1 Once you have agreed to enter the trial, your treatment is not chosen by yourself or a doctor but by a computer. There
is usually a 50:50 chance of receiving either treatment
Royal Marsden Website, 2003
2 Once you have agreed to enter the trial, a computer will allocate you randomly (as if by the roll of a dice) to receive the
‘standard treatment’ or one of the new treatments being tested. Neither your doctor nor you yourself will choose
which treatment you receive
MRC FOCUS Trial Patient info
sheet
3 Once you have agreed to enter the trial, you will be randomised to a course of treatment. This is a process that assigns
participants by chance, rather than by choice, to either the investigational group or the control group
NCI website, 2003
4 Once you have agreed to enter the trial the decision regarding which treatment you receive will be made by a process
called ‘randomisation’. This means that your specialists will not make the decision themselves, but it will be made by
chance
BNL Trial Patient info sheet
5 Once you have agreed to enter the trial, the treatment you receive will be selected by a process called randomisation,
that is, it will not be chosen by you or your doctor, but by a computer and it is like the toss of a coin. This is to prevent
bias in the results of the trial
CLL4 Trial Patient info sheet
6 Once you have agreed to enter the trial, you will be randomised to a course of treatment. This means that there are at
least two different groups in the trial and those taking part are put into one or other group at random. This
‘randomisation’ is usually done by a computer
CancerHelp website, 2003
7 Once you have agreed to enter the trial, you will be randomised to a course of treatment. This means that a computer
will randomly allocate patients to treatment groups in the trial. This is done so that each group has a similar mix of
patients of different ages, sex and state of health
CancerBACUP website, 2003
Table 2 Patient demographic information
N¼600 (%)
Sex
Male 226 37.7
Female 337 56.2
Missing 37 6.2
Previous trial experience 169 28.2
Age
Under 60 years 298 49.7
60 years and over 273 45.5
Missing 29 4.8
Cancer site
Breast 220 36.7 (15)
GI/colorectal 76 12.7 (16)
Gynaecological 33 5.5 (6)
Lung 30 5.0 (14)
Urological 121 20.2 (15)
Haematological 35 5.8 (6)
Muscular/skeletal 22 3.7 ( )
Brain 10 1.7 (2)
Other 21 3.5
Missing 32 5.3
Regions of UK
Southern England
(inc. London)
295 49.25
Midlands 74 12.35
Northern England 110 18.4
Scotland 47 7.8
Wales 73 12.2
Missing 1
N italics, UK incidence (CRUK, 2001).
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sPreferred description
The w
2 analysis showed a significant difference both for preference
and dislike across the descriptions (preferred X
2¼199.74, df¼6,
Po0.0001; disliked X
2¼251.22, df¼6, Po0.0001). Table 3 dis-
plays the frequency counts of preferences for each statement, 497
patients nominated both their most preferred and most disliked
descriptions, two patients disliked all of them, 56 did not express
any preference, 36 only nominated a preferred description and 10
patients gave only their most disliked description.
The most preferred description was that found on the
CancerBACUP website (28% (151 out of 533)). Reasons patients
gave for their choice included ‘it explains how and why’, ‘it
explains why treatment is randomly allocated to patients’ and ‘it
sounds as if there is a sense and a meaning for the computer
choosing a treatment’. Also, this description was one of only two
that did not mention the word ‘chance’ or use an analogy for
chance. It also explains the need for randomisation that is the
prevention of bias. Significant numbers of patients also favoured
the descriptions on the Royal Marsden website (20% (106 out of
533)) and that given in the MRC Focus Trial information sheet
(19% (101 out of 533)).
Most disliked description
Description 3 from the National Cancer Institute (NCI) website
was the most disliked (38% (193 out of 508)) and this was
consistent regardless of cancer site, age, previous trial experience
or sociodemographic characteristics. This is one of the shortest
descriptions but was repeatedly criticised by patients for using
unfamiliar language and terminology ‘too technical’, ‘used long
complicated words and terms’ and ‘its use of language assumes
knowledge of the research process’.
DISCUSSION
Explaining clearly the concept of randomisation is fundamental to
ensuring properly educated consent to clinical trial participation,
yet studies have shown that despite different verbal and written
explanations, patients still remain confused and unclear about the
phrases used (Featherstone and Donovan, 2002; Simon et al, 2004).
In the survey reported here, most descriptions in current use are
viewed as clear, but patients have preferences for some rather than
others. The CancerBACUP website (2003) provided the most
preferred description of randomisation irrespective of age, sex or
cancer site and previous trial experience, while that found on the
NCI website (2003) was the most disliked description.
In contrast to our previous study, the description that included
the analogy ‘toss of a coin’ did not produce such fervent dislike by
the majority of patients (Jenkins et al, 2002). One explanation is
that the analogy did not stand alone, it was prefaced by the
statement that a computer would choose ‘like the toss of a coin’
together with an explanation that it is done to prevent bias.
Patients who did dislike it expressed similar comments to those
found in the previous survey such as ‘My life should not depend on
the ‘toss of a coin’, ‘the roll of a dice’ or chance.’
The NCI description found favour with a mere 17 (3%) of the
sample and overshadowed all others for dislike. In particular,
patients did not like the use of what they felt was jargon and
several commented that, ‘the English was a bit too complex’.
Given the multinational nature of many RCTs and a desire for
uniformity of patient information accompanying them, some
crosscultural research on descriptions of randomisation might be
warranted. The language in the description from an American
website was especially disliked by UK patients, which could
produce a potential barrier to participation in trials.
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